Your browser is no longer supported. Please, upgrade your browser.
NBRV Nabriva Therapeutics plc daily Stock Chart
Nabriva Therapeutics plc
Index- P/E- EPS (ttm)-0.76 Insider Own1.50% Shs Outstand150.78M Perf Week-6.05%
Market Cap67.10M Forward P/E- EPS next Y-0.35 Insider Trans-0.46% Shs Float148.96M Perf Month-21.09%
Income-74.70M PEG- EPS next Q-0.10 Inst Own29.00% Short Float5.18% Perf Quarter-30.98%
Sales2.90M P/S23.14 EPS this Y50.60% Inst Trans-2.22% Short Ratio4.40 Perf Half Y-63.07%
Book/sh0.25 P/B1.68 EPS next Y34.00% ROA-116.30% Target Price- Perf Year-78.74%
Cash/sh0.26 P/C1.63 EPS next 5Y- ROE-210.60% 52W Range0.39 - 2.11 Perf YTD-68.11%
Dividend- P/FCF- EPS past 5Y31.10% ROI-105.00% 52W High-80.05% Beta2.07
Dividend %- Quick Ratio4.40 Sales past 5Y31.60% Gross Margin84.30% 52W Low9.21% ATR0.04
Employees162 Current Ratio4.90 Sales Q/Q-81.20% Oper. Margin- RSI (14)39.64 Volatility10.54% 8.61%
OptionableYes Debt/Eq0.21 EPS Q/Q62.20% Profit Margin- Rel Volume1.76 Prev Close0.45
ShortableYes LT Debt/Eq0.21 EarningsNov 05 AMC Payout- Avg Volume1.75M Price0.42
Recom2.80 SMA20-7.71% SMA50-19.11% SMA200-40.81% Volume3,076,252 Change-6.44%
Mar-19-20Downgrade Wedbush Outperform → Neutral
May-02-19Upgrade Gabelli & Co Sell → Hold
May-02-19Reiterated H.C. Wainwright Buy $9 → $7
Sep-07-18Resumed Morgan Stanley Overweight
Mar-21-18Initiated BofA/Merrill Buy $10
Jan-17-18Initiated Morgan Stanley Overweight
Nov-01-17Reiterated H.C. Wainwright Buy $18 → $20
Aug-25-17Initiated SunTrust Buy $20
Feb-01-17Reiterated Wedbush Outperform $13
Oct-27-16Resumed Leerink Partners Outperform $14
Sep-08-16Initiated H.C. Wainwright Buy $16
Jan-27-16Initiated Gabelli & Co Buy $14
Nov-12-15Reiterated RBC Capital Mkts Outperform $21 → $22
Oct-13-15Initiated Wedbush Outperform
Oct-13-15Initiated RBC Capital Mkts Outperform $21
Oct-13-15Initiated Leerink Partners Outperform $19
Oct-12-15Initiated Needham Buy $15
Nov-12-20 07:01AM  
Nov-05-20 04:01PM  
Nov-03-20 06:06AM  
Nov-02-20 04:01PM  
Oct-13-20 07:00AM  
Sep-10-20 08:39AM  
Aug-31-20 07:00AM  
Aug-06-20 04:01PM  
Aug-03-20 07:00AM  
Jul-30-20 04:01PM  
Jul-29-20 10:21AM  
Jul-28-20 10:02AM  
Jul-23-20 07:00AM  
Jul-17-20 11:12AM  
Jul-16-20 04:04PM  
Jul-15-20 04:01PM  
Jun-23-20 09:12PM  
Jun-22-20 03:23PM  
Jun-19-20 08:52PM  
Jun-10-20 08:39AM  
Jun-08-20 07:19AM  
Jun-01-20 04:00PM  
May-29-20 07:31PM  
May-27-20 04:01PM  
May-18-20 08:00AM  
May-11-20 04:01PM  
May-08-20 07:00AM  
May-07-20 08:32AM  
May-05-20 07:00AM  
Apr-14-20 08:59AM  
Apr-09-20 07:00AM  
Apr-08-20 07:00AM  
Apr-02-20 10:08AM  
Mar-17-20 09:33AM  
Mar-12-20 04:01PM  
Mar-10-20 04:01PM  
Mar-05-20 08:21AM  
Mar-03-20 09:38AM  
Mar-02-20 04:01PM  
Feb-05-20 04:01PM  
Jan-22-20 08:24AM  
Jan-09-20 08:39AM  
Jan-08-20 04:01PM  
Dec-20-19 03:06PM  
Dec-19-19 09:38PM  
Dec-10-19 10:31AM  
Dec-02-19 04:01PM  
Nov-23-19 06:55PM  
Nov-21-19 04:01PM  
Nov-20-19 07:49PM  
Nov-18-19 07:00AM  
Nov-12-19 04:01PM  
Nov-01-19 04:01PM  
Oct-31-19 07:00AM  
Oct-15-19 07:00AM  
Oct-11-19 06:32PM  
Oct-01-19 04:01PM  
Sep-27-19 12:15PM  
Sep-26-19 04:01PM  
Sep-18-19 07:00AM  
Sep-11-19 09:32AM  
Sep-09-19 07:00AM  
Sep-06-19 04:01PM  
Aug-29-19 09:15AM  
Aug-28-19 07:00AM  
Aug-21-19 12:15PM  
Aug-20-19 04:47PM  
Aug-19-19 08:33PM  
Aug-17-19 01:46PM  
Aug-16-19 11:17AM  
Aug-14-19 01:02PM  
Aug-08-19 07:00AM  
Aug-06-19 07:00AM  
Jul-18-19 02:36PM  
Jul-17-19 04:02PM  
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; for the treatment of acute bacterial skin and skin structure infection; and that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, osteomyelitis, and prosthetic joint infections. It is also developing CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Broom Colin MDDirectorAug 20Sale0.6511,0647,165248,936Aug 21 07:02 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.